Gary Brandt

Gary Brandt is an experienced professional in computational and medicinal chemistry, currently serving as Executive Director of Computational Chemistry at DICE Therapeutics, Inc., with a progression from Senior Director and Director roles since June 2021. Prior to DICE, Gary held the position of Director of Computational and Medicinal Chemistry at Bolt Biotherapeutics, focusing on the design of small molecule components of ISACs, and acted as Director and Head of the Department of Medicinal Chemistry at BlackThorn Therapeutics, contributing to the care of patients with neurobehavioral disorders. Gary's earlier roles included various positions at Theravance Biopharma, where strategic influence and research in locally restricted compounds were key, as well as post-doctoral research at Emory University on anti-viral agents and a research associate role at Deciphera Pharmaceuticals working on kinase inhibitors. Gary holds a Ph.D. in Medicinal Chemistry from The University of Kansas and a B.S. in Chemistry from Georgia State University.